Current and future therapeutic strategies for treating mixed cryoglobulinemia

Bibliography

• Ramos-Casals M, Stone JH, Cid MC, et al. The cryoglobulinaemias. Lancet 2012;379(9813):348-60
   PubMed Web of Science ®Google Scholar
• Damoiseaux J, Cohen Tervaert JW. Diagnostics and treatment of cryoglobulinaemia: it takes two to tango. Clin Rev Allergy Immunol 2013
   Web of Science ®Google Scholar
• Saadoun D, Delluc A, Piette JC, et al. Treatment of hepatitis C-associated mixed cryoglobulinemia vasculitis. Curr Opin Rheumatol 2008;20(1):23-8
   PubMed Web of Science ®Google Scholar
• Sansonno D, Dammacco F. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis 2005;5(4):227-36
   PubMed Web of Science ®Google Scholar
• Saadoun D, Sellam J, Ghillani-Dalbin P, et al. Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. Arch Intern Med 2006;166(19):2101-8
   PubMedGoogle Scholar
• Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002;25(6):909-13
   PubMed Web of Science ®Google Scholar
• Misiani R, Bellavita P, Fenili D, et al. Interferon alpha-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994;330(11):751-6
   PubMed Web of Science ®Google Scholar
• Zuckerman E, Keren D, Slobodin G, et al. Treatment of refractory, symptomatic, hepatitis C virus related mixed cryoglobulinemia with ribavirin and interferon-alpha. J Rheumatol 2000;27(9):2172-8
   PubMed Web of Science ®Google Scholar
• Naarendorp M, Kallemuchikkal U, Nuovo GJ, et al. Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection. J Rheumatol 2001;28(11):2466-73
   PubMed Web of Science ®Google Scholar
• Cacoub P, Lidove O, Maisonobe T, et al. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis. Arthritis Rheum 2002;46(12):3317-26
   PubMed Web of Science ®Google Scholar
• Bruchfeld A, Lindahl K, Stahle L, et al. Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency. Nephrol Dial Transplant 2003;18(8):1573-80
   PubMed Web of Science ®Google Scholar
• Alric L, Plaisier E, Thebault S, et al. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004;43(4):617-23
   PubMed Web of Science ®Google Scholar
• Mazzaro C, Zorat F, Caizzi M, et al. Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study. J Hepatol 2005;42(5):632-8
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Thibault V, et al. Antiviral therapy for hepatitis C virus–associated mixed cryoglobulinemia vasculitis: a long-term followup study. Arthritis Rheum 2006;54(11):3696-706
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Thibault V, et al. Peg-IFNalpha/ribavirin/protease inhibitor combination in hepatitis C virus associated mixed cryoglobulinemia vasculitis: results at week 24. Ann Rheum Dis 2014;73(1):24-30
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14(Suppl 1):s64-72
   PubMed Web of Science ®Google Scholar
• Tarantino A, Campise M, Banfi G, et al. Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis. Kidney Int 1995;47(2):618-23
   PubMed Web of Science ®Google Scholar
• Dammacco F, Sansonno D, Han JH, et al. Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 1994;84(10):3336-43
   PubMed Web of Science ®Google Scholar
• Casato M, Agnello V, Pucillo LP, et al. Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997;90(10):3865-73
   PubMed Web of Science ®Google Scholar
• Hausfater P, Cacoub P, Assogba U, et al. Plasma exchange and interferon-alpha pharmacokinetics in patients with hepatitis C virus-associated systemic vasculitis. Nephron 2002;91(4):627-30
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827-34
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101(10):3818-26
   PubMed Web of Science ®Google Scholar
• Ferri C, Cacoub P, Mazzaro C, et al. Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. Autoimmun Rev 2011;11(1):48-55
   PubMed Web of Science ®Google Scholar
• Cacoub P, Delluc A, Saadoun D, et al. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand? Ann Rheum Dis 2008;67(3):283-7
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Landau D, et al. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 2008;111(11):5334-41
   PubMed Web of Science ®Google Scholar
• De Vita S, Quartuccio L, Isola M, et al. A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 2012;64(3):843-53
   PubMed Web of Science ®Google Scholar
• Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum 2012;64(3):835-42
   PubMed Web of Science ®Google Scholar
• Visentini M, Granata M, Veneziano ML, et al. Efficacy of low-dose rituximab for mixed cryoglobulinemia. Clin Immunol 2007;125(1):30-3
   PubMed Web of Science ®Google Scholar
• Visentini M, Ludovisi S, Petrarca A, et al. A phase II, single-arm multicenter study of low-dose rituximab for refractory mixed cryoglobulinemia secondary to hepatitis C virus infection. Autoimmun Rev 2011;10(11):714-19
   PubMed Web of Science ®Google Scholar
• Petrarca A, Rigacci L, Caini P, et al. Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease. Blood 2010;116(3):335-42
   PubMed Web of Science ®Google Scholar
• Sene D, Ghillani-Dalbin P, Amoura Z, et al. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009;60(12):3848-55
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche-Rigon M, Sene D, et al. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008;67(10):1431-6
   PubMed Web of Science ®Google Scholar
• Saadoun D, Resche Rigon M, Sene D, et al. Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia. Blood 2010;116(3):326-34; quiz 504-325
   PubMed Web of Science ®Google Scholar
• Dammacco F, Tucci FA, Lauletta G, et al. Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. Blood 2010;116(3):343-53
   PubMed Web of Science ®Google Scholar
• Saadoun D, Rosenzwajg M, Joly F, et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med 2011;365(22):2067-77
   PubMed Web of Science ®Google Scholar
• Saadoun D, Pineton de Chambrun M, Hermine O, et al. Using rituximab plus fludarabine and cyclophosphamide as a treatment for refractory mixed cryoglobulinemia associated with lymphoma. Arthritis Care Res (Hoboken) 2012;65(4):643-7
   Web of Science ®Google Scholar
• Terrier B, Krastinova E, Marie I, et al. Management of noninfectious mixed cryoglobulinemia vasculitis: data from 242 cases included in the CryoVas survey. Blood 2012;119(25):5996-6004
   PubMed Web of Science ®Google Scholar
• Nehme-Schuster H, Korganow AS, Pasquali JL, et al. Rituximab inefficiency during type I cryoglobulinaemia. Rheumatology (Oxford) 2005;44(3):410-11
   PubMed Web of Science ®Google Scholar
• Landau DA, Saadoun D, Halfon P, et al. Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response. Arthritis Rheum 2008;58(2):604-11
   PubMed Web of Science ®Google Scholar